Clinical Trial: BCMA/CD3 BsAb Therapy for POEMS Syndrome

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07115654) titled 'BCMA/CD3 BsAb Therapy for POEMS Syndrome' on Aug. 04.

Brief Summary: This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.

Study Start Date: Aug. 10

Study Type: INTERVENTIONAL

Condition: POEMS Syndrome

Intervention: DRUG: CM336 (BCMA/CD3 bispecific antibody)

CM336 is a bispecific antibody targeting BCMA and CD3, designed to redirect T cells to eliminate abnormal plasma cells.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Published by HT D...